|By PR Newswire||
|February 18, 2014 11:33 AM EST||
DURHAM, N.C., Feb. 18, 2014 /PRNewswire-iReach/ -- Health Decisions, Inc., the full-service clinical research organization of choice for forward-looking biopharma and medical device companies, today announced the appointment of Patrick Phillips, D Phil, as Vice President, Clinical Affairs.
"We are delighted to add a clinical affairs executive with outstanding capabilities, deep global experience and expertise in the management of studies across the therapeutic spectrum," said Health Decisions CEO Michael Rosenberg, MD, MPH. "Patrick's insights and capabilities will greatly strengthen our clinical operations. Equally important, Patrick is an innovator committed to achieving both high efficiency and high quality in clinical trials. He will fit in perfectly at Health Decisions."
"I look forward to working closely with Michael and the entire Health Decisions clinical team," Dr. Phillips said. "Health Decisions is an innovative CRO where adaptive design combined with an integrated technology platform that fully enables the application of adaptive operations provides a best-in-class approach to study planning and execution."
Dr. Phillips will be responsible for oversight and leadership of clinical affairs, biometrics and data management at Health Decisions. He will provide guidance and direction for all aspects of these departments with a focus on continuous process improvement and global scalability. Dr. Phillips will analyze, plan and develop strategy for clinical program goals, including data-driven global performance management and quality improvement programs. He will also set priorities aligned to strategic imperatives and ensure that Health Decisions' services meet the strategic and operational goals of study sponsors.
In more than 19 years of experience in global clinical research, Dr. Phillips has worked for large pharma, small biotech and large global CROs. He has experience leading operational delivery in both Europe and the United States. His managerial responsibilities have included comprehensive responsibility for clinical operations in trials in all phases, all major therapeutic areas and both early and later phase development. In his most recent role, Dr. Phillips was responsible for leading clinical trial delivery in the United States for Boehringer Ingelheim across their entire therapeutic portfolio. His recent experience includes providing senior operational oversight for trials in CNS, infectious disease, oncology, endocrine and metabolism, cardiovascular, respiratory and nephrology.
Among Dr. Phillips' notable accomplishments is leadership of successful initiatives that enable operational excellence and best practice and deliver consistency, quality and performance in global trials. Companies for which Dr. Phillips has exercised senior operational responsibilities include Boehringer Ingelheim, Array BioPharma and GlaxoSmithKline. Dr. Phillips has also been responsible for managing strategic client relationships in his role with a large global CRO.
Dr. Phillips serves on advisory boards for key industry conferences on clinical execution and disruptive innovation. His honors include the prestigious GlaxoSmithKline Platinum Impact Award, the highest GSK award recognizing excellence in R&D. Dr. Phillips holds a D Phil degree in Clinical Biochemistry from the University of Oxford in England.
About Health Decisions
Health Decisions is the CRO of choice for forward-looking biopharma and medical device companies and a driving force in the modernization of clinical development. Health Decisions uses data-driven insight and agility to deliver clinical development success, reduce timelines and risk and increase quality and returns for biopharma and device companies worldwide. For 25 years and in more than 300 clinical trials involving tens of thousands of patients in many therapeutic areas, Health Decisions has improved the efficiency of clinical development through innovative methodology, processes and technology. Health Decisions' clinical-development services have enabled biopharma and device companies to bring new products to market faster and at lower cost, thus providing the public with earlier access to improved treatments and diagnostics at more affordable prices. Health Decision won the prestigious 2013 CIO 100 Award for delivering true business value through its innovative Agile Risk-Based Monitoring+ technology. Privately held, Health Decisions is headquartered in Durham, NC and operates on five continents.
Media Contact: Leslie Hammill, Health Decisions, 9199671111 ext. 520, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Health Decisions